Last reviewed · How we verify
esomeprazole 20 mg
Esomeprazole 20 mg, marketed by AstraZeneca, is a well-established drug in the proton pump inhibitor class. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in generic competition following the patent expiry.
At a glance
| Generic name | esomeprazole 20 mg |
|---|---|
| Also known as | Nexium |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (NA)
- A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer (PHASE3)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection (NA)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- esomeprazole 20 mg CI brief — competitive landscape report
- esomeprazole 20 mg updates RSS · CI watch RSS
- AstraZeneca portfolio CI